2023
1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study
Grigoleit G, Kluger H, Thomas S, Chesney J, Domingo-Musibay E, Sanmamed M, Medina T, Ziemer M, Whitman E, Finckenstein F, Chou J, Wu X, Sulur G, Shi W, Sarnaik A. 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study. Annals Of Oncology 2023, 34: s654. DOI: 10.1016/j.annonc.2023.09.2220.Peer-Reviewed Original Research
2022
789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)
Sarnaik A, Lewis K, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan G, Kirkwood J, Hassel J, Orloff M, Larkin J, Weber J, Furness A, Khushalani N, Medina T, Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Chesney J. 789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study). 2022, a821-a822. DOI: 10.1136/jitc-2022-sitc2022.0789.Peer-Reviewed Original Research
2020
P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Medina T, Thomas S, Pavlick A, Whitman E, Algarra S, Corrie P, Hamid O, Lutzky J, Olah J, Weber J, Larkin J, Shi W, DiTrapani K, Qin H, Mirgoli M, Wu R, Takamura T, Fardis M, Kirkwood J. P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update. Journal For ImmunoTherapy Of Cancer 2020, 8: a12. DOI: 10.1136/lba2019.18.Peer-Reviewed Original Research